This week, we have three interviews to mark Stand Up To Cancer Day. We have conversations with Simon Kerry, co-founder and CEO of Curve Therapeutics; Poolbeg Pharma CEO Jeremy Skillington; and Stefano Gulla, CSO of Kling Biotherapeutics.
Interview times:
03:12 Curve Therapeutics
21:32 Kling Bio
37:10 Poolbeg Pharma
Microcycles to address cancer
Curve Therapeutics, a private biotechnology company using its gene-encoded Microcycle discovery platform to build a pipeline of innovative cyclic peptide and small molecule drugs to address high priority intracellular disease targets, with an initial focus on cancer, immunology, and inflammation.
Addressing cancer treatment side effects
Poolbeg Pharma is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs.
The company’s clinical programmes target large addressable markets including, cancer immunotherapy-induced cytokine release syndrome and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide GLP-1R agonist.
The role of B-cells in beating cancer
Kling Biotherapeutics is a biotech company developing antibody-based drugs for cancer and infectious diseases.
Through its proprietary primary B-cell platform technologies, the company combines high-efficiency B-cell immortalization with functional, antibody-first screening to uncover novel antibody–antigen pairs.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
